Predictive Oncology Launches Innovative Specialty Media for Growing Ovarian Tumors in the Lab
February 05 2020 - 8:30AM
TumorGenesis, Inc. a subsidiary of Predictive Oncology, Inc.
(NASDAQ: POAI) has selected US Biological Corporation of Salem,
Massachusetts as the manufacturer and distributor of its innovative
culture media for growing ovarian tumor cells.
Unlike traditional cell culture media, which select for one or
two fast growing cell types, TumorGenesis media are specially
formulated to help researchers isolate and maintain the unique
histological and basic biological signatures of heterogeneous
ovarian cell types while growing them in the
laboratory.
“Using these proprietary media our partners have identified 25
cell types from ovarian tumors, which to a large degree have never
been screened or studied by researchers,” said Richard Gabriel,
President of TumorGenesis, Inc. “The resulting cells have a 95+%
match to cells found in patient bodies.”
Available for purchase via US Biological in Q1-2020, the new
media are being launched at a time when, according to MarketWatch,
the global cell culture media market is growing at a healthy 8.4%
CAGR, driven mainly by the increased use of biological based drugs
such as immune therapies, and is expected to reach US $2,360
Million by 2024.
While specialty media is a small subset of the market, Gabriel
sees this ovarian-specific formulation as the first in a portfolio
of tools and services TumorGenesis will offer to cancer
researchers. “We believe by helping researchers develop cells and
tumors that more closely mimic cells and tumor found in patient
bodies, we can help lower the cost and speed the discovery of drugs
and therapies that will approve patient outcomes.”
About Predictive Oncology
Inc.
Predictive Oncology (Nasdaq: POAI) operates through five
segments (Domestic, International, Clinical, CRO and DCHIP), which
contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical
and Skyline Europe. Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by
providing an evidence-based roadmap for therapy. In addition to its
proprietary precision oncology platform, Helomics offers boutique
CRO services that leverage its TruTumor™, patient-derived tumor
models coupled to a wide range of multi-omics assays (genomics,
proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform (D- CHIP) to provide a tailored solution to
its clients’ specific needs. Predictive Oncology’s TumorGenesis
subsidiary is developing a new rapid approach to growing tumors in
the laboratory, which essentially “fools” cancer cells into
thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform kits will assist researchers
and clinicians to identify which cancer cells bind to specific
biomarkers. Once the biomarkers are identified they can be used in
TumorGenesis’ Oncology Capture Technology Platforms which isolate
and help categorize an individual patient’s heterogeneous tumor
samples to enable the development of patient specific treatment
options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented
and FDA cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through
both domestic and international divisions. The company has achieved
sales in five of the seven continents through both direct sales and
distributor partners. For more information, please visit
www.predictive-oncology.com.
Forward-looking Statements
Certain of the matters discussed in the press release contain
forward-looking statements that involve material risks to and
uncertainties in the Company’s business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Risks and uncertainties relating to a
transaction with Quantitative Medicine include no assurance that a
transaction will be completed or, if completed, no assurance that
the acquisition of Quantitative Medicine would result in
anticipated benefits. Further, the acquisition could involve
unanticipated costs, distractions to Company management or other
risks or adverse effects, and any issuance of equity securities in
the transaction would result in dilution to the Company’s
stockholders, which may be significant. Other risks and
uncertainties regarding the Company’s securities include (i) risks
related to the recent merger with Helomics, including the fact that
the combined company will not be able to continue operating without
additional financing; possible failure to realize anticipated
benefits of the merger; costs associated with the merger may be
higher than expected; the merger may result in disruption of the
Company’s and Helomics’ existing businesses, distraction of
management and diversion of resources; and the market price of the
Company’s common stock may decline as a result of the merger;
(ii) risks related to our partnerships with other companies,
including the need to negotiate the definitive agreements; possible
failure to realize anticipated benefits of these partnerships; and
costs of providing funding to our partner companies, which may
never be repaid or provide anticipated returns; and (iii) other
risks and uncertainties relating to the Company that include, among
other things, current negative operating cash flows and a need for
additional funding to finance our operating plan; the terms of any
further financing, which may be highly dilutive and may include
onerous terms; unexpected costs and operating deficits, and lower
than expected sales and revenues; sales cycles that can be longer
than expected, resulting in delays in projected sales or failure to
make such sales; uncertain willingness and ability of customers to
adopt new technologies and other factors that may affect further
market acceptance, if our product is not accepted by our potential
customers, it is unlikely that we will ever become profitable;
adverse economic conditions; adverse results of any legal
proceedings; the volatility of our operating results and financial
condition; inability to attract or retain qualified senior
management personnel, including sales and marketing personnel; our
ability to establish and maintain the proprietary nature of our
technology through the patent process, as well as our ability to
possibly license from others patents and patent applications
necessary to develop products; Predictive’s ability to implement
its long range business plan for various applications of its
technology; Predictive’s ability to enter into agreements with any
necessary marketing and/or distribution partners and with any
strategic or joint venture partners; the impact of competition, the
obtaining and maintenance of any necessary regulatory clearances
applicable to applications of Predictive’s technology; and
management of growth and other risks and uncertainties that may be
detailed from time to time in the Company’s reports filed with the
SEC, which are available for review at www.sec.gov. This is not a
solicitation to buy or sell securities and does not purport to be
an analysis of Predictive’s financial position. See Predictive’s
most recent Annual Report on Form 10-K, and subsequent reports and
other filings at www.sec.gov.
Contact:
Bob Myers 651-389-4800bmyers@skylinemedical.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024